T Foltynie

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging
    Christian Lambert
    Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology, London, UK
    Neuroimage 60:83-94. 2012
  2. ncbi request reprint Surgical management of Parkinson's disease
    Thomas Foltynie
    UCL Institute of Neurology, Queen Square, London, UK
    Expert Rev Neurother 10:903-14. 2010
  3. doi request reprint MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety
    T Foltynie
    Unit of Functional Neurosurgery, Sobell Department of Motor Neuroscience, Box 146, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    J Neurol Neurosurg Psychiatry 82:358-63. 2011
  4. doi request reprint BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, Cambridge, UK
    J Neurol Neurosurg Psychiatry 80:141-4. 2009
  5. doi request reprint Gender differences in quality of life following subthalamic stimulation for Parkinson's disease
    G M Hariz
    Department of Community Medicine and Rehabilitation, Occupational Therapy, Umea University, Umea, Sweden Department of Clinical Neuroscience, Umea University, Umea, Sweden UCL Institute of Neurology, Queen Square, London, UK
    Acta Neurol Scand 128:281-5. 2013
  6. pmc Saccadic latency distributions in Parkinson's disease and the effects of L-dopa
    A W Michell
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, CB2 2PY, Cambridge, UK
    Exp Brain Res 174:7-18. 2006
  7. pmc Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease
    E Tripoliti
    Sobell Department, Unit of Functional Neurosurgery, UCL Institute of Neurology, Box 146, Queen Square, London, WC1N 3BG, UK
    Neurology 76:80-6. 2011
  8. ncbi request reprint Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Brain 130:1787-98. 2007
  9. pmc Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 77:665-7. 2006
  10. pmc Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
    S J G Lewis
    Cambridge Centre for Brain Repair, Forvie Site, Addenbrooke s Hospital, Cambridge, CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 76:343-8. 2005

Collaborators

Detail Information

Publications14

  1. pmc Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging
    Christian Lambert
    Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology, London, UK
    Neuroimage 60:83-94. 2012
    ....
  2. ncbi request reprint Surgical management of Parkinson's disease
    Thomas Foltynie
    UCL Institute of Neurology, Queen Square, London, UK
    Expert Rev Neurother 10:903-14. 2010
    ..We also provide details of our practice, including patient selection, surgical technique and postoperative stimulation programming and medication adjustment. Current and possible future alternatives to DBS of the STN are also discussed...
  3. doi request reprint MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety
    T Foltynie
    Unit of Functional Neurosurgery, Sobell Department of Motor Neuroscience, Box 146, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    J Neurol Neurosurg Psychiatry 82:358-63. 2011
    ....
  4. doi request reprint BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, Cambridge, UK
    J Neurol Neurosurg Psychiatry 80:141-4. 2009
    ..There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF)...
  5. doi request reprint Gender differences in quality of life following subthalamic stimulation for Parkinson's disease
    G M Hariz
    Department of Community Medicine and Rehabilitation, Occupational Therapy, Umea University, Umea, Sweden Department of Clinical Neuroscience, Umea University, Umea, Sweden UCL Institute of Neurology, Queen Square, London, UK
    Acta Neurol Scand 128:281-5. 2013
    ..Here, we investigate possible differences between women and men undergoing STN DBS, with respect to health-related quality of life...
  6. pmc Saccadic latency distributions in Parkinson's disease and the effects of L-dopa
    A W Michell
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, CB2 2PY, Cambridge, UK
    Exp Brain Res 174:7-18. 2006
    ....
  7. pmc Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease
    E Tripoliti
    Sobell Department, Unit of Functional Neurosurgery, UCL Institute of Neurology, Box 146, Queen Square, London, WC1N 3BG, UK
    Neurology 76:80-6. 2011
    ..Here we prospectively examined the short- and long-term speech response to STN-DBS in a consecutive series of patients to identify clinical and surgical factors associated with speech change...
  8. ncbi request reprint Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Brain 130:1787-98. 2007
    ..Furthermore, given that these predictors of dementia are readily measurable within just a few minutes in a clinical setting, our work may ultimately have practical implications in terms of guiding prognosis in individual patients...
  9. pmc Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 77:665-7. 2006
    ..The true prevalence of the mutation in idiopathic disease, its penetrance, and the phenotypic heterogeneity of associated cases have important implications for genetic screening in the clinical field...
  10. pmc Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
    S J G Lewis
    Cambridge Centre for Brain Repair, Forvie Site, Addenbrooke s Hospital, Cambridge, CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 76:343-8. 2005
    ..To investigate the heterogeneity of idiopathic Parkinson's disease (PD) in a data driven manner among a cohort of patients in the early clinical stages of the disease meeting established diagnostic criteria...
  11. pmc Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients
    A Eusebio
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK
    J Neurol Neurosurg Psychiatry 82:569-73. 2011
    ..One possibility is that DBS suppresses local pathologically synchronised oscillatory activity...
  12. ncbi request reprint Biomarkers and Parkinson's disease
    A W Michell
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, CB2 2PY, UK
    Brain 127:1693-705. 2004
    ..In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives...
  13. pmc The genetic basis of Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    J Neurol Neurosurg Psychiatry 73:363-70. 2002
    ..The identification of such susceptibility genes will eventually enable us to more accurately classify this complex disease...
  14. pmc Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series
    T Foltynie
    Sobell Department of Motor Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Parkinsons Dis 2013:362908. 2013
    ..Since LCIG is an expensive option, development of the most appropriate future commissioning of this therapy in the absence of Class 1 evidence requires careful scrutiny of the outcomes of its use in a broad range of published series...